Boehringer Ingelheim GmbH
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Boehringer Ingelheim GmbH
Pharma will partner with SyntheX on targeted protein degradation, with Autolus on cell therapy safety. Novo Nordisk gets rights to Ventus’s lead compound in NASH and chronic kidney disease.
How do you send 90,000 employees home and still bring a COVID-19 vaccine to market in record time? Pfizer showed the way and at a recent virtual event, senior vice-president Robert Brown revealed how the "secret sauce" of digitalization continues to help cut medical legal review times, crunch clinical trial duration and reduce service interruptions.
Futura Medical is preparing to seek approval from the FDA to launch OTC in the US its MED3000 erectile dysfunction treatment, marketed in Europe under the Eroxon brand name. After completing all the necessary studies demonstrating that the gel-based, drug-free product works as a self-care treatment for ED, Futura says it is confident that the soon to be submitted de novo medical device application will be successful and pave the way for a Q1 2023 launch.
Many gene therapies companies have faced R&D and financial problems this year but the longer term potential of the field and low prices might tempt big pharma into deals.
- Other Names / Subsidiaries
- Abexxa Biologics Inc
- AMAL Therapeutics SA
- ICD Therapeutics
- NBE Therapeutics AG
- SSP Co., Ltd.
- Vira Therapeutics GmbH (Vira T)